October 31, 2006

Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir

Key Points

Key points are not available for this paper at this time.

Abstract

Coadministration of TDF with LPV/r resulted in increased tenofovir exposures at steady state, possibly through increased absorption. This increase is not believed to be clinically relevant based on the safety and efficacy of TDF plus LPV/r-containing regimens in HIV-infected patients in long-term controlled clinical trials.

Bookmark

Cite This Study

Kearney et al. (Tue,) studied this question.

synapsesocial.com/papers/69de40d7da08968cf7b0be8e https://doi.org/https://doi.org/10.1097/01.qai.0000243103.03265.2b

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen2004 · 21 citations
2Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients2002 · 154 citations
3Prediction of Creatinine Clearance from Serum Creatinine2008 · 15,393 citations
4Tenofovir Disoproxil Fumarate2003 · 161 citations
5Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection2000 · 3,328 citations

Bookmark